Puma Biotechnology Presents Results from the HRPositive Subgroup in Phase III Trial of Neratinib for HER2Amplified Early Stage Breast Cancer

Puma Biotechnology Presents Results from the HR-Positive Subgroup in Phase III Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer

13:41 EST 6 Dec 2018 | Speciality Pharma Journal

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from the subgroup of patients with hormone receptor positive (HR-positive) breast cancer from the Company’s Phase III ExteNET Trial of neratinib for early stage HER2-Amplified breast cancer are being presented at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently …

More From BioPortfolio on "Puma Biotechnology Presents Results from the HR-Positive Subgroup in Phase III Trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer"